The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo
Nov 04, 2024•over 1 year ago
Contract Type
agreement
New YorkBiotechnologyHealthcarePharmaceuticalBiopharma
Description
Royalty Pharma and Syndax Pharmaceuticals have entered into a $350 million synthetic royalty funding agreement for Niktimvo, a first-in-class product with the potential to address the serious and devastating complications associated with chronic GVHD. This agreement will fund Syndax through profitability and ensure participation in the profits from Niktimvo, while Royalty Pharma will receive a 13.8% royalty on U.S. net sales of Niktimvo.
Company Information
Company
Syndax Pharmaceuticals
Location
New York, New York, United States
About
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment.
New YorkBiotechnologyHealthcarePharmaceuticalBiopharma